CALCISCON (Switzerland) develops products targeting calcification, with a focus on solutions for improved management of kidney patients. T50 is a revolutionary blood test for the assessment of calcification-related cardiovascular risk.
Clinical studies with over 13,000 patients across 9 studies, showed that T50 was best-in-class predictor of poor outcome among kidney patients. Calciscon is developing an algorithm for predicting the efficacy of calcification therapies, with the potential to avoid many cardiovascular events.
The T50 test and algorithm are not FDA approved.
Additional Info
First-time Exhibitor:
Yes